What are the potential side effects when adding a mineralocorticoid receptor antagonist to existing antihypertensive therapy?
The potential side effects when adding a mineralocorticoid receptor antagonist (MRA) to existing antihypertensive therapy include hyperkalemia and a reversible decline in kidney function, particularly among patients with low eGFR. MRAs should not be used in patients with high risk of hyperkalemia (e.g., hypoaldosteronism or type 4 renal tubular acidosis).